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Abstract
Preventive chemotherapy (PCT) programmes are used to control five of the highest burden neglected tropical diseases
(NTDs): soil-transmitted helminth infections (hookworm, ascariasis, and trichuriasis), lymphatic filariasis, schistosomiasis,
onchocerciasis, and trachoma. Over the past decade, new resource commitments for the NTDs have enabled such
programmes to intensify their control efforts, and for some diseases, to shift from goals of morbidity control to the
interruption of transmission and elimination. To successfully eliminate the parasite reservoir, these programmes will
undoubtedly require prolonged, high treatment coverage. However, it is important to consider that even when
coverage levels reach an acceptable proportion of the target population, there may be a considerable gap
between coverage (those who receive the drug) and compliance (those who actually consume the drug)—a
topic of fundamental and perhaps underestimated importance. We conducted a systematic review of published
literature that investigated compliance to PCT programmes for NTD control and elimination. Databases searched
included PubMed/Medline, Web of Knowledge (including Web of Science), OVID, and Scopus. Data were collected on
compliance rates, reasons for non-compliance, as well as the heterogeneity of compliance definitions and calculations
across programmes and studies. A total of 112 studies were selected for inclusion. The findings of the review revealed
substantial heterogeneity across compliance terms and definitions; an imbalance of available studies for particular
disease areas and countries; and finally, a lack of longitudinal compliance studies to properly investigate the
role of systematic non-compliance. The lack of consistency among reporting of compliance data can result in
under- or over-estimating compliance in a population, and therefore has serious implications for setting and
reaching elimination targets. Reframing of the guidelines on compliance definitions coupled with an urgent
call for longitudinal research in systematic non-compliance should be essential elements in the programmatic
shift from control to elimination.
Keywords: Compliance, Coverage, Systematic non-compliance, NTDs, Helminths, Preventive chemotherapy,
Mass drug administration, Elimination, Systematic review
Introduction
The neglected tropical diseases (NTDs) affect over 1.4 bil-
lion of the world’s poorest people—including 800 million
children [1, 2]. These diseases can cause long-term disabil-
ity and are estimated to account for over 500,000 deaths
per year [1]. Infection can lead to malnutrition, cognitive
impairment, and poor school attendance—effectively
trapping individuals in a cycle of poverty and associated
disease [2, 3].
Preventive chemotherapy (PCT) programmes are used to
control five of the highest burden NTDs: soil-transmitted
helminth infections (STH) including hookworm, ascariasis,
and trichuriasis species, lymphatic filariasis (LF), schisto-
somiasis (SCH), onchocerciasis or river blindness (RB), and
trachoma. Preventive chemotherapy, often provided
through mass drug administration (MDA), is given regard-
less of whether or not the individuals are infected. It can be
aimed at a particular occupational or age group that may
represent those most at-risk of heavy infection and
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concomitant morbidity (often children). The level and
mechanism of PCT delivery may depend on local policies,
resources, and disease endemicity [3, 4].
Generally, the drugs are given as a single dose at regu-
lar intervals, usually annually or bi-annually, again de-
pending on national policies, transmission dynamics in a
defined setting and endemicity [4]. Co-endemicity and
polyparasitism are common in many populations; in
such cases, there are advantages to integrating multiple
PCT-dependent interventions, which can include cost
savings of up to 50 % [2, 4–6].
The last decade has seen a period of intensifying treat-
ment coverage and new resource commitments for NTD
control. The spirit of this expanded effort is captured in
the London Declaration of January 2012, where many
philanthropic organisations, pharmaceutical companies
(who make drug donations), as well as government and
international agencies pledged further commitments to
achieve new goals of control and/or elimination of ten of
the highest burden NTDs by the year 2020. These goals
were inspired by the World Health Organization’s
(WHO) 2020 road map for accelerating work to over-
come the global burden of NTDs [7]. This has enabled
programmes to intensify their control efforts, and for
some diseases, the goals have now shifted from morbid-
ity control to the interruption of transmission and
elimination of the parasite reservoir altogether [4, 7].
The success of elimination programmes may be influ-
enced by a wide range of factors such as initial levels of
endemicity and transmission intensities in the local envir-
onment; heterogeneities of host exposure, susceptibility,
and predisposition; vector/intermediate host competence,
treatment frequency, duration, coverage and compliance,
among others [2, 4, 8]. In particular, coverage is a com-
monly reported metric and a key determinant for achiev-
ing programme targets [9, 10]. Figure 1 shows annual
PCT coverage by disease from 2008 to 2013 [11]. Success-
ful elimination programmes will undoubtedly require
prolonged, optimised treatment coverage—a claim widely
supported by findings in the mathematical modelling
literature on the impact of PCT on parasite transmission
dynamics [8, 12–14]. Between 2011 and 2013, over 700
million people received PCT annually—representing only
about 37 % of the 1.902 billion people across 125 coun-
tries who require annual treatment [3, 15]; the focus is
now on scaling up NTD programme coverage [16].
However, it is important to note that even when cover-
age levels reach a significant fraction of the target popula-
tion, there may be a considerable gap between coverage
and compliance—a topic of fundamental and perhaps
underestimated importance. Babu and Babu [17] recently
explored this topic in a comprehensive review of PCT
programmes for LF in India. The authors point out that in
the context of India’s MDA Programme to Eliminate
Lymphatic Filariasis (PELF), ‘reported coverage’ (total
population to whom the drugs are delivered) is not an
accurate reflection of the actual number of people con-
suming the drug. Consequently, ‘coverage’ and ‘compli-
ance’ were devised as two distinct indices of PCT—the
former referring to the proportion of eligible people who
received tablets, and ‘compliance’ referring to the propor-
tion of eligible people who actually ingested the tablets.
Similarly, Brieger et al. explain that while reports of PCT
coverage for onchocerciasis are encouraging, these rates
may not give the full picture of the success of PCT due to
the groups of individuals who systematically fail to comply
over the years of the programme [18]. If a significant pro-
portion of a community continually fails to comply with
treatment, a portion of the parasite reservoir remains
untreated and thus allows potential recrudescence via
continued transmission, thereby reducing the pro-
gramme’s chances at achieving elimination [17, 19]. The
implications could be even more severe if one considers,
for example, the possibility that those who do not comply
with treatment are heavily infected individuals who
experience side effects on first treatment, they may
continue to be non-compliant in future rounds. Al-
though it has not been quantified, the contribution of
Overall PCT
Fig. 1 Yearly coverage of preventive chemotherapy in the NTDs. The graph shows PCT coverage from 2008 to 2013 by disease and total
coverage (indicated by ‘PCT’). Adapted from [11]
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non-compliance (and to an even larger extent, persist-
ent non-compliance) to transmission and its threat to
elimination is likely substantial [10]. Drug compliance
is, arguably, the best indicator of how well PCT is
implemented; some studies have estimated 80 % to be
an adequate level of drug compliance [20, 21].
The heterogeneity of language used to describe the
concept of compliance is of fundamental importance to
both the evaluation of PCT and for reaching targets and
achieving elimination goals. Many publications have dis-
cussed the inconsistencies in the reporting of compliance
rates and the range of language used to describe the con-
cept of “medication-taking” [17, 22–28]. Two of the most
commonly used and commonly debated terms are ‘com-
pliance’ and ‘adherence’. Many argue that ‘compliance’,
and in some cases both terms [27], may exaggerate the
role of the physician and his/her control over the process
of taking medication [22, 23, 28], and that none of these
terms accurately represent patients’ motivations for
choosing to take or not to take their medication [27].
Table 1 summarises some of the most common terms
employed throughout the literature. These issues will be
discussed further in subsequent sections of the review.
Quantifying and understanding reasons behind compli-
ance/non-compliance with PCT is of paramount import-
ance, now more than ever, as NTD programme goals
continue to shift from control to elimination. There is
considerable literature on PCT coverage, compliance and
associated factors; however, there are few comprehensive
reviews on compliance rates thus far ([17, 25]), and none
which address multiple NTDs and delivery methods
(community- and school-based). The objective of this
paper is to systematically review the published informa-
tion on compliance with PCT, with a particular focus on
longitudinal studies in order to investigate systematic
non-compliance, for lymphatic filariasis, soil-transmitted
helminths (hookworm, ascariasis, and trichuriasis), schis-
tosomiasis, onchocerciasis, and trachoma.
Review
We conducted a systematic review of published litera-
ture that investigated compliance to PCT programmes
for NTD control and elimination. Data were collected
on compliance rates, reasons for non-compliance, as
well as the heterogeneity of compliance definitions and
calculations across programmes and studies. The
authors followed the guidelines under the PRISMA
Statement for Reporting Systematic Reviews and Meta-
Analysis. The completed PRISMA checklist is available
in Additional file 1.
Criteria for selection of studies
Papers investigating compliance to community- and/or
school-based PCT programmes that reported primary
compliance data were eligible for inclusion. If these ini-
tial criteria were met, we also included quantitative data
on the reasons for non-compliance and/or the presence
of statistically supported compliance-related factors
(only if clear that factors were assessed in their relation
to compliance, not coverage). Studies reporting data on
coverage were excluded unless the metric used was
explicitly defined as capturing those who complied/
ingested the drug, not simply having received it (e.g.
studies using terms ‘drug coverage’ or ‘treatment cover-
age’ were often included as these are terms for compli-
ance used by the Global Programme for Elimination of
Lymphatic Filariasis (GPELF) and in most cases could be
interpreted as referring to those who ingested the drug).
Studies evaluating alternative interventions such as in-
creased sensitisation/education or different recruitment
strategies to improve aspects of PCT were excluded, un-
less the rates for the control arm (standard PCT-only)
were reported separately. Due to the number of overall
studies, purely qualitative studies were excluded, as were
studies evaluating selective PCT (screening followed by
treatment of infected individuals only). The set of LF
publications from India was primarily based on the
Table 1 Relevant terms/definitions used in medication-taking literature and sources
Term Definition References and comments
Compliance Defined as “the extent to which a person’s behaviour – taking
medication, following a diet, and/or executing lifestyle
changes—coincides with medical or health advice”
[22, 28]; some argue it suggests the patient has a passive
role in following provider’s orders
Adherence Defined as “the extent to which a person’s behaviour – taking
medication, following a diet, and/or executing lifestyle changes,
corresponds with agreed recommendations from a health care
provider”
[62] merged definition based on Haynes [63] and Rand
[64]; preferred by some as they argue it suggests the
patient is a more active partner in the decision-making
Concordance Defined as “a negotiated, shared agreement between clinician
and patient concerning treatment regimens, outcomes, and
behaviours; a more cooperative relationship than those based
on issues of compliance”
[65, 66] Royal Pharmaceutical Society of Great Britain’s
working Party on medicine-taking; relatively recent term
introduced by [66] to replace compliance
Other terms used to
describe medication-taking:
Patient participation, acceptance, uptake, consumption
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collection included in Babu and Babu’s 2013 review (this
was assumed to be comprehensive); in addition, LF stud-
ies based in others countries during this time period, as
well as studies completed after this publication were
considered for inclusion. Case control studies which
purposively selected compliant and non-compliant
groups for further analysis were excluded, as were
studies which elicited general compliance data over a
non-specified time period (e.g. ‘have you ever taken
drugs for [LF, onchocerciasis, etc.] before?’). In addition,
some studies were excluded on the basis of other study
design factors such as extremely small sample size or
requirements to pay a fee for treatment.
Literature search and selection of articles
A systematic search of databases including PubMed/
Medline, Web of Knowledge (including Web of Science),
OVID, and Scopus was performed using the following
key words (and possible variants of the terms including
alternate species names): soil-transmitted helminths,
helminths, ascaris, hookworm, trichuris, onchocerciasis,
river blindness, schistosomiasis, bilharzia, elephantia-
sis, lymphatic filariasis, trachoma AND compliance,
non-compliance, non-compliers, adherence, non-adherence,
refusal, medication adherence. The full search strategy is
included in Additional file 2. Papers published up to
21st April 2015 and available in English or French
were considered.
Selection and extraction of data
The literature selection process is outlined in Fig. 2. The
search generated 4664 citations (excluding duplicates).
These studies were initially retrieved and reviewed at
title and abstract level (consulting the full text if no ab-
stract was included). In the second round, 368 articles
were read in full and assessed for eligibility. A fur-
ther22 papers were identified from reference lists of
other papers (totalling 390 for review). An additional
round of full-text review was completed on 264 papers,
and a total of 112 papers were eventually included in
the final count.
A data extraction form was developed in Microsoft
Excel and included four major components: compliance/
non-compliance rate, reasons given for low/non-compli-
ance, whether the study included statistical analysis of fac-
tors associated with compliance/non-compliance, as well
as notes on how compliance was defined in the studies.
Due to the wide range and heterogeneity of the factors
associated with compliance found in the literature, these
data were not reported in full. Other details of the publica-
tion and PCT were also included (see Table 2 for
summary; full data table in Additional file 3).
Data synthesis and definitions
For the purpose of this paper, the authors’ use of the
term ‘compliance’ refers to the proportion of individuals
who swallow the medications (whereas ‘coverage’ refers
purely to drug delivery: the proportion of individuals
who receive the drug). Due to the heterogeneity of defi-
nitions and terms used through the collection of studies,
it is important to note that the denominators used are,
in some papers the total population, and in others the
eligible population. These issues will be addressed
further in the discussion.
As one of the main themes of the paper is to highlight
the inconsistencies in definitions and calculations of com-
pliance, the data are reported as they were in the original
publication since it was not possible to re-analyse or
standardise the data in all studies. At times, the calcula-
tion of compliance data or statistics associated with
compliance-related factors were unclear. However, the
authors did their best to accurately represent the results
given the available information.
Results
A total of 112 studies met the criteria for inclusion in
the review (Fig. 2). The majority of the studies were
selected through the search of databases, but some
additional relevant studies (22) were identified through
references listed in the selected papers.
Characteristics of included studies
Details of the selection of papers are shown in
Additional file 3. The study designs of the selected
papers included cross-sectional studies, intervention
studies, coverage surveys of various types, and house-
hold surveys, with use of both self-reported question-
naires and directly-observed treatment. The search
retrieved 36 longitudinal studies (reporting more than
one round of PCT) accounting for 32 % of the total
studies. The papers reported on evaluations of PCT/
MDA rounds carried out from 1987 to 2013 in 30 coun-
tries with almost half the studies coming from India
(50). The full breakdown of studies by country is shown
in Fig. 3. The number of studies by disease and year are
shown in Fig. 4 for all studies, and in Fig. 5 for multiple-
round/longitudinal studies only. In terms of method of
delivery, the majority of studies were community-based
or -directed PCT (including central distribution points)
as compared to school-based studies which were only
three. The identified studies were very heterogeneous in
terms of outcome variables (see Fig. 6 for details).
Compliance rates and metrics
The selection of studies revealed a wide range of compli-
ance data. The rates presented ranged from 19.5 to 99 %
compliance (or a similar metric). There was, however,
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considerable variation in the terminology and definitions
used. Due to such heterogeneity, it was not possible to
comparatively assess the data, especially when authors
fail to define the terms or metrics used in their analysis.
Approximately a quarter of the studies in the review were
classified as having unclear compliance data—meaning the
metric or denominators used were not defined and unable
to be inferred from the paper. A further set of studies (40)
were previously excluded due to even greater degrees of
ambiguity regarding definitions and calculations.
Longitudinal studies
There were a total of 36 selected studies which assessed
more than one round of PCT/MDA with the majority
coming from the LF (17) and onchocerciasis (14) litera-
ture. These studies are shown by PCT duration and dis-
ease in Fig. 5 (three of the 36 studies were excluded in
the figure due to unspecified programme dates). The
duration of PCT covered in the selection of studies
ranged from one year (using bi-annual treatment) to
14 years. Despite reporting compliance rates over
multiple time points/rounds of PCT, the majority of
these studies assessed compliance retrospectively and
not annually at each PCT round. Specific examples and
the implications of this methodology are discussed
further in subsequent sections.
Reasons for and factors associated with low/non-compliance
Approximately 56 % (63/112) of the selected studies re-
ported quantitative data on reasons for non-compliance/
non-consumption (i.e. percentage distribution). Other
studies provided only qualitative or anecdotal data on
reasons for low or non-compliance, and these papers
were excluded from the review. The studies revealed
a range of reasons given for non-compliance or non-
consumption including programme-level issues and
individual-level characteristics. The former included
comments relating to the methods of delivery or
distribution, the motivation and/or perception of
drugs distributors or health staff, the availability of drugs,
the use of directly-observed or supervised therapy.
Individual-level characteristics ranged from awareness and
Fig. 2 Selection of studies for inclusion in the review. PRISMA flow diagram outlining the literature selection process
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Table 2 Subset of data extraction table –five of 112 studies shown (full table in Additional file 3)
Reference Publication
Year
Country MDA
Year(s)
Disease Drugs
delivereda
Method of
delivery
Sampleb Compliance rate Reasons for non-compliance Predictors of
compliance (y/n)c
Notes on metrics/
definitions
[31] 2008 Nigeria 1996–2004 RB IVM Community 4800 surveyed 49.96 % overall
participation
n/a No Presented as ‘coverage’
yet discussed as
‘participation’
[32] 2007 Sri Lanka 2003 LF DEC +
ALB
Community 4358 surveyed 71.4 % Taking other medication
(3.1 %), felt they did not
need them (3.2 %), had
forgotten to consume
them (1.1 %), worried
about adverse effects
(0.8 %)
No Compliance: those who
consumed drug over
eligible population
[34] 2013 India 2008 LF DEC Community 571 eligible 42.3 % No motivation (24.7 %),
drugs not supplied (22.5 %),
absence at home (13.5 %),
no faith (10.1 %), fear of
side effects (10.1 %) and
others: Forgotten, lack of
prior IEC etc. (7.8 %), illness
(7.3 %), wrong information
(3.9 %)
No Compliance:
consumption of drug
among those who
received drug; defaulter:
did not consume drug,
or partially consumed
drug, or those who
were not supplied the
drug by the drug
distributors
[30] 1991 Liberia 1987–1989 RB IVM Community 1987: 13,704;
1988: 13,977;
1989: 14,110
1987: 96.8 % (56.2 %
of total pop); 1988:
96.6 % (57.7 % of total
pop); 1989: 98.4 %
(70.9 % of total pop)
n/a No Referred to as ‘those
who accepted treatment’
using eligible population
as denominator
[53] 2006 India 2001–2003 LF DEC/DEC
+ ALB
Community unspecified MDA rounds 1–3
consumption rate:
34.9 %, 39.8 %, 41.7 %
(of total population);
35.5 %, 40.3 %, 42.4 %
(of eligible); 46.9 %,
51.7 %, 50 % (of drug
recipients)
MDA rounds 1–3: not
necessary (31.8 %, 52.9 %,
42.9 %), fear of side reactions
(24.6 %, 20.7 %,
30.1 %), treatment for other
diseases (8.9 %, 4.4 %, 11.3 %),
no opinion/no response
(19.2 %, 2.5 %, 6.5 %),
partial consumption (6.6 %,
4.4 %, 5.6 %), others (8.9 %,
15.1 %, 3.6 %)
No Referred to as
consumption rate and
presented in terms of
total population, of
eligible population, and
of those who received
drug
asome studies may involve combinations of drugs (i.e. DEC + ALB) yet refer to only one drug (i.e. DEC) in the paper; the table includes only those drugs specifically named in the studies
bwhen available, the surveyed/interviewed population was taken as the sample; otherwise, eligible or total study population was taken
conly when statistically supported
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knowledge of the disease or PCT programme, perception
of risk and benefit of PCT, and drug-related concerns such
as forgetting to take the drug, feeling the drug is unneces-
sary, general dislike of taking drugs/swallowing tablets, fear
of taking drugs when ill, and most notably, fear of side
effects or adverse events. Fear of side effects (often
times based on previous experience of side effects)
was among the reasons for non-compliance with
MDA for the majority of LF and onchocerciasis stud-
ies which used combinations of albendazole (ALB),
1985 1987 1989 1991 1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015
Year of MDA
STH
Onchocerciasis
Schistosomiasis
LF
Fig. 5 Duration of longitudinal studies by disease. The studies include those for which the PCT start and end year were available
Fig. 6 Combinations of numerator/denominator and respective terms employed in the selection of studies. The coloured arrows and boxes represent the
various combinations and resulting terms that researchers have employed in the calculation of compliance, or other ‘medication-taking’ terms.*‘Number
who received’ represents the most “selective” denominator. The bolded terms resulting from this metric (number who ingested/number who received)
therefore capture the most accurate measure of compliance
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diethylcarbamazine (DEC), and/or ivermectin (IVM).
However, these were also the disease areas which
more commonly reported such data; whereas, the se-
lected schistosomiasis, STH, and trachoma papers
rarely included assessments of reasons for non-
compliance. Reported side effects/adverse reactions
from IVM commonly included itching, rash, body
pain, fever, headache, swellings, dizziness, and weakness
[29–31]. For DEC and ALB regimens, participants re-
ported fever, headache, giddiness, nausea, vomiting, diar-
rhoea, sleepiness, fatigue, swelling, and myalgia [32–34].
Thirty-one percent (35/112) of the selected studies in-
cluded statistically-supported data on factors associated
with compliance (or with different types of ‘coverage’).
These studies involved univariate or multivariate analyses
of demographic variables (such as age, gender, education,
religion, ownership of land, etc.) and/or individual charac-
teristics or behavioural factors (such as perceived risks
and benefits of the disease or PCT programme, knowledge
of disease transmission, prevention or treatment, type of
recruitment or drug distributor, etc.). As would be
expected, these factors show considerable overlap with
reasons given for non-compliance; for this reason and due
to previous comprehensive reviews on the subject [25], it
was decided that this component of compliance is beyond
the scope of the current paper, and only the presence or
absence of this data was recorded for each study.
Interpretation of the data presented in the selected
publications
The findings of this systematic review revealed substantial
heterogeneity across compliance terms and definitions; an
imbalance of available studies for particular disease areas
and countries, with a much higher concentration of
studies on LF and onchocerciasis and based in India; and
finally, a lack of longitudinal compliance studies to prop-
erly investigate the role of systematic non-compliance.
Most striking was the limited number of compliance stu-
dies—and specifically of longitudinal cohort-based studies
(following individuals over time)—for schistosome
infections (three total; one longitudinal) and STH (six
total; four longitudinal) where PCT coverage has in-
creased significantly in recent years [35, 36]. In addition,
we found very few studies with school-based or mixed
(community + school) delivery with three papers each.
Compliance terminology and definitions
It is important to be aware of the widespread heterogen-
eity of coverage versus compliance definitions and calcula-
tions throughout the literature. A significant number of
papers report ‘coverage’ rates while actually representing
‘compliance’—calculating those who ingest medication
and not just receive it, for example—but then referring to
it as ‘coverage’, or vice versa. For example, a study states
that a high level of compliance to the drug was achieved,
yet then refers to the percentage of those who received the
drug (not ingested). In some studies, it seems this vari-
ation in terminology may be due to an intervention design
of directly observed/supervised treatment. Therefore,
when reporting ‘coverage’ rates, one is assuming the
consumption of the drug was ~100 %, as the process was
directly observed. In this scenario, one may argue there is
less of a need to distinguish between receiving and
consuming, and between coverage and compliance. This
was often the case for many onchocerciasis studies (and
some LF studies) which likely followed the African
Programme for Onchocerciasis Control (APOC) model of
Community-Directed Treatment with Ivermectin (CDTI)
which specifies directly-observed treatment (DOT). How-
ever, for other studies, this was not clear—the treatment
distribution and recording process was not well described
and it was not possible to assign studies to a DOT
category. Our argument for better distinction between
metrics is aimed rather at studies where treatment was
not directly observed, or studies where it was impossible
to know whether treatment was observed or not. Never-
theless, the type of distribution (e.g. DOT) and the metrics
used should be well defined and clarified in the reporting
of programme data. It is important to note, that in
other areas of repeated chemotherapy (such as for
HIV and non-infectious conditions like high blood
pressure or other chronic illnesses), modern methods
of measuring compliance, and the difference between
receipt of the drug and consumption of the drug, are
well documented [37–41].
Due to such variations in the definitions for compliance
used in the papers, it was challenging to make any
comparisons of the data. A true comparative assessment
cannot be done across studies which use different defini-
tions or equations of compliance, especially when the au-
thors fail to even define the metric used. A meta-analysis
would, therefore, be unrealistic. Krentel et al. discuss simi-
lar issues of heterogeneity of terms and definitions; they
emphasise the importance of distinguishing between
coverage (defined as “delivery of medicine”) and compli-
ance (defined as “ingestion of pills”). The authors further
illustrate the importance of this distinction when consid-
ering the simulation model LYMFASIM, which estimates
the impact of PCT on infection and transmission rates by
using as a key input “the fraction of people treated per
round” [42]. According to the WHO, this calculation is
equivalent to ‘epidemiological drug coverage’ (see Table 3)
and captures those who actually swallow the drug
while ‘reported coverage’ may not include this specifi-
cation [25, 43]. Krentel et al. argues that differences
in these two metrics may explain in some part the
persistence of LF transmission after multiple rounds
of PCT in some countries despite high reported
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coverage rates [25]. Table 3 highlights the varying
types of ‘coverage’ reported in PCT evaluations which
are commonly used to convey the concept of
medication-taking. These definitions are primarily
based on the GPELF guidelines; it is important to
note that these terms are also employed outside the
LF literature, but they are often used inconsistently in
both contexts.
Compliance/coverage denominators
Perhaps the most important component of coverage and
compliance calculations (which varies by programme
and study) is the denominator. Figure 6 shows the differ-
ent combinations of compliance (or medication-taking
terms) used in the selection of studies. Some studies
counted as their numerator the number of people
receiving the drug (i.e. coverage); others specified the
number of people ingesting/swallowing the drug; while
others failed to specify or used ambiguous terms such as
‘number participated’ or ‘number treated.’ To calculate
the rate of medication-taking, researchers generally di-
vided this data by: 1) the total population, 2) the eligible
population, 3) the number of people who received the
drug, or oftentimes, 4) an unspecified denominator. The
coloured arrows and boxes represent the various combi-
nations and resulting terms that researchers have
employed for that calculation. It is important to note
that some studies calculated compliance rates using the
total surveyed population (through household question-
naires, for example) as the denominator which is a
logical and accurate representation of the compliance
given the data collected. Nevertheless, it is clear that the
term ‘compliance’ is used (often inaccurately) for differ-
ent combinations of numerator and denominator—as it
appears in all boxes.
Alexander (2015) [26] comments on the difference
in using eligible population (drug coverage) versus
total population (epidemiological drug coverage) as
denominators—the latter of which corresponds to the
original LF modelling study [14] establishing the 65 %
minimum effective coverage for elimination. He warns
against the potential confusion and misreporting of
coverage/compliance with regards to Transmission
Assessment Surveys (TAS) methodology, suggesting
that progress could be overestimated and TAS could
be done prematurely if not based on GPELF’s ‘epidemio-
logical drug coverage’ [26]. In this review, we observed a
considerable number of LF (and some onchocerciasis)
studies which shared a uniform set of definitions and met-
rics. This is undoubtedly due to the presence of GPELF
definitions and guidelines (Table 3). However, the overall
selection of studies across multiple diseases represented a
largely heterogeneous set of compliance outputs and
definitions as evident in Fig. 6.
Ideal compliance metrics
Koroma and colleagues state that the best measure of
how well PCT programmes are implemented is the ‘drug
coverage’—number who ingested the drug over the tar-
geted or eligible population—and that it should be close
to 100 %; whereas an adequate level of ‘epidemiological
drug coverage’ (using total population as the denomin-
ator) is estimated to be 80 % [44]. In their review, Babu
and Babu focus on the coverage-compliance gap (i.e. the
difference between those who receive the drug and those
who actually consume the drug) as the primary metric
for capturing the proportion of people who receive but
do not ingest. Over a total of 36 studies, coverage ranged
from 48.8 to 98.8 % whereas compliance was, on aver-
age, 22 % lower [17]. This is probably the most ideal and
useful measure of true ‘compliance’ but required the au-
thors to re-calculate many of the papers’ compliance
rates so as to have consistent denominators and a
uniform metric for comparison. In their recalculations,
they chose what some of the research community refers
to as ‘effective coverage’ as their standard metric for
Table 3 Various types of coverage terms used in PCT evaluations and definitions based on GPELF (Global Programme to Eliminate LF)
Coverage term Definition References and comments
Reported coverage “Intervention coverage calculated from data reported by all drug
distributors”
[43]; often much higher than compliance/drug
coverage/survey coverage
Programme coverage/
epidemiological drug
coverage
“Proportion of individuals in the implementation unit who have
ingested the MDA drugs of the total population in the
implementation unit”
[43]; denominator is total population
Drug coverage “Proportion of individuals, expressed as a percentage, in a targeted
population who swallowed a drug, or a combination of drugs”
[43]; denominator is eligible/targeted population
Surveyed coverage “Total number of individuals identified by household survey as
having ingested the drugs over the total number of individuals
residing in all the surveyed households about whom information
on drug ingestion could be elicited”
Relies on self-reporting by participants; subject to recall
bias or participants’ assumptions about correct answers
to give [25, 43]
Geographical coverage “Proportion of administrative units that are implementing MDA
of all those that require MDA.”
[43]; focus on distribution rather than ingestion
Adapted from [25]
Shuford et al. Parasites & Vectors  (2016) 9:29 Page 10 of 16
comparison—reporting those who ingested the drug
over the eligible population.
Considering the variation in terminology, one could
argue that each definition or calculation may have its
place in representing different aspects of coverage and
compliance—useful at different levels of programme de-
sign and evaluation. For example, using total population
as the denominator may have greater epidemiological
value in showing the proportion of those at risk being
covered by PCT, whereas employing eligible population
may be more valuable in assessing the effectiveness of
the programme. Finally, using the most selective denom-
inator of drug recipients provides a more individual level
of acceptability and compliance—enabling researchers to
capture those who choose not to take the drug but only
if they have been offered it in the first place. This is a
much more accurate representation of drug refusal and
would better inform programme design and implementa-
tion—and more specifically, in the context of community
sensitisation.
The lack of consistency among reporting of compliance
data, however, can result in under- or over-estimating
compliance in a population, and therefore has serious im-
plications for setting and reaching elimination targets. The
authors would support Krentel’s recommendations for the
research community and national programmes to agree
on a uniform set of definitions, but also a standardised
method of reporting compliance. As Krentel et al. point
out, the WHO guidelines [43] are a starting point
(summarised in Table 3); evidence of this consistency in
definitions is seen in some of the onchocerciasis and LF
literature as many studies report comparable rates of both
compliance and multiple types of coverage. However, the
authors would argue for greater clarification of the distinc-
tion between various forms of coverage and compliance to
improve understanding. There should be much greater
focus on the standardisation of terms and definitions so as
to facilitate reliable comparative studies.
Ideal study design
In addition to employing the correct compliance metrics,
it is of equal importance to consider the best study design
for investigating systematic non-compliance in ongoing
control programmes. There is a need for longitudinal co-
hort studies, following the same individuals over time,
stratified by a set of socio-demographic factors (see Fig. 7).
There is perhaps a trade-off between the ideal timeline
(many years of data) and the need to understand the ex-
tent of and reasons for systematic non-compliance
quickly. Depending on the frequency of treatment, a
couple years or perhaps three time points could be suffi-
cient for getting an initial understanding of the issue, but
ideally, data would be captured continuously over the
duration of the programme.
Data analysis would aim to quantify ‘predisposition’ by
calculating the probability of not complying (through a
non-parametric test of correlation between the likeli-
hood of taking the drug at time points t1, t2, t3 etc. using
Kendal’s Tau test). An individual’s predisposition could
be further categorised into levels of low/medium/high
based on relevant socio-demographic or behavioural
factors found to influence compliance—which are cru-
cial for a comprehensive understanding of systematic
non-compliance.
Reasons for and factors associated with non-compliance
In addition to the heterogeneity of compliance rates, an
unexpected finding from this review was also the hetero-
geneity in the (reporting of) reasons for non-compliance.
For example, some studies include ‘not receiving tablets’
as a reason for non-compliance, whereas others more pre-
cisely consider this a reason for non-coverage. In the latter
case, only reasons for not consuming/ingesting the drug
would be classified as non-compliance. It is also of interest
to note that among the reasons given for non-compliance
(or non-coverage) were problems with drug delivery (e.g.
‘distributor did not come’ or ‘treatment not supervised’).
In this case, considering APOC’s CDTI model of directly-
observed treatment, one may argue that what is truly at
play here is ‘non-compliance’ or ‘non-adherence’ to treat-
ment guidelines by the part of the drug distributor. This
may be an important contribution to future work on
understanding the complexities behind compliance and
how it’s reported.
Although rarely mentioned by respondents, another rea-
son for non-compliance is already having received treat-
ment by sources other than nationally-run STH control
programmes. “Unprogrammed deworming” occurs fre-
quently, and although it may play an important role in the
absence of government deworming, it may also overesti-
mate the effectiveness of PCT [45] and has complicated
implications on reports of coverage and compliance. This
is undoubtedly another crucial area that will require
further attention and research.
As previously mentioned, reasons given for low/non-
compliance are understandably linked with many of the fac-
tors demonstrated to be associated with non-compliance.
Similar to Krentel’s findings on LF compliance studies, the
factors identified in this review ranged from wider
programme and delivery issues to individual recipient
demographics and characteristics such as awareness and
knowledge, perceived benefits and risks, adverse events,
and personal situations [25]. In their assessment of factors
related to continuing transmission of LF in Haiti, Boyd et
al. reflect on the most common reason given for non-
compliance which was “Don’t Know”—and question
whether it could be a proxy for “Don’t Care” or whether
there is some other determinant of compliance that isn’t
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being captured by the research [46]. There is increasing
awareness of the importance in assessing these factors
alongside compliance rates (as evidenced by the consider-
able number of selected studies from all disease categories
which reported on these). As previously discussed, further
in-depth research of these factors will be a fundamental
component of potential investigations into predisposition.
Systematic non-compliance
There were very few reliable longitudinal studies
reported in the literature. Brieger et al. comments on the
lack of recent large-scale, long-term studies of annual
compliance with ivermectin [47], and the authors would
add, to a much greater degree for studies of compliance
with other drugs and helminth programmes. In the early
years of onchocerciasis programmes, there were not
enough annual distributions to give useful measures of
compliance. However, once the original MDA projects
were in operation for over a decade, annual compliance
studies became more feasible [18, 48].
The majority of longitudinal studies which aim to asses
systematic non-compliance do so through retrospective
methodology whereby participants are asked at one point
in time about compliance with several previous PCT
rounds (or assessed through previous treatment registers)
[24, 46, 48–52]. This approach introduces multiple bia-
ses—most notably, the challenge of recalling specific PCT
rounds over previous years, especially in areas where mul-
tiple disease control programmes may be in operation at
various times throughout the year. In addition, there is the
bias resulting from the people not reached by the surveys
(who may also likely be hard to reach during treatment),
although they may be counted towards the denominator
of the compliance rate. Conversely, those who are not sur-
veyed will not contribute to the numerator of the compli-
ance rate, regardless of their treatment status—a critical
detail in data collection and reporting which should be in-
corporated into programme and study design. Some stud-
ies attempt to compare survey responses to treatment
registers; however, these were often incomplete and unre-
liable [53]. Brieger and colleagues found that only 67.2 %
of people recalled the same number of treatments received
as that recorded in the register; 16.2 % recalled more treat-
ments than recorded while another 16.2 % reported taking
IVM fewer times than recorded [49]. As previously dis-
cussed, a more rigorous study design would consist of
regular surveys conducted immediately following each
round of treatment. This was rarely seen in the selected
studies, although two examples include Regu et al.’s three-
year compliance study for LF in Kerala State [54] and
Simonsen et al.’s assessment of six treatment rounds for
LF control in Tanzania [55]. In each study, a selection of
participants were interviewed shortly after each MDA to
assess individual compliance with the drug.
Individual compliance can be inferred from long-term
coverage data; however, as Brieger et al. points out, we
cannot learn about the factors influencing systematic
non-compliance unless there are longitudinal data on
the same individuals [47]. Mathieu and colleagues [24]
comment on the uncertainty of the effect of systematic
non-compliers on elimination in the absence of informa-
tion about the infectious status of these individuals. It is
unlikely, however, that those who systematically fail to
comply would have lower infection levels than those
who routinely participate in PCT [24]—indeed the
converse may apply in many settings (e.g. if predisposed
to heavy infection). This is evidenced by studies in Haiti
and Egypt, where compared with compliant individuals,
those who were systematically non-compliant had higher
infection levels [25, 46, 56] and were also less aware that
the drugs could prevent LF and that they must be taken
yearly [24].
There is an urgent need to better identify, under-
stand, and develop strategies against systematic non-
compliance in order to prevent it from jeopardising
elimination efforts. The authors would support
Kyelem and colleagues’ remarks concerning the need
for a better quantitative understanding of the levels
of PCT compliance required to interrupt transmis-
sion—but perhaps more challengingly, the levels of
non-compliance or systematic non-compliance that
would still permit elimination [57].
Fig. 7 Ideal study design for investigating systematic non-compliance. The figure represents a longitudinal cohort study, following the same individuals
over time, stratified by a set of socio-demographic factors. Compliance surveys should be conducted following each treatment round to
provide a minimum of three time points
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Recently, both Stolk et al. and Coffeng et al. have
discussed modelling approaches for understanding
compliance patterns (for onchocerciasis and hookworm,
respectively), incorporating the role of a ‘lifelong compli-
ance factor,’ as well as age and gender, into the probabil-
ity that an individual participates in treatment [58, 59].
Ideally, this factor captures the effect of a range of indi-
vidual and sociological factors which may influence
compliance (such as education, family circumstances, or
access to treatment). Using WORMSIM, a generalized
individual-based modelling framework for transmission
and control of helminths, Coffeng and colleagues illus-
trated how systematic (non-) participation in PCT with
albendazole can considerably reduce the impact of PCT
regardless of treatment frequency.
Figure 8 shows an alternative approach to modelling
STH transmission dynamics which incorporates this
lifelong compliance factor and follows a formulation by
Plaisier et al. [60]. The likelihood of elimination is
presented across three compliance settings: random, in
which the attending individuals are selected randomly at
each treatment; fully systematic, in which individuals ei-
ther attend all treatments or none; and semi-systematic
(a much more plausible scenario), in which individuals
attend each treatment according to a lifetime measure of
their likelihood to comply (i.e. the compliance or
‘attendance factor’ as Plaisier et al. describe it).
In the context of reaching elimination goals, it is also
important to consider the potential impact and benefit
of alternative treatment strategies such as increasing fre-
quency of treatment (i.e. bi-annual or four-monthly) [8],
or using longer lasting drugs such as moxidectin [61].
The authors support previous calls for more and better
programmatic data on individual compliance patterns
within such scenarios in order to inform the mathemat-
ical models used to determine the impact of (non-) com-
pliance on elimination [58, 59] (as models can impact
the benefit of changing strategy).
Limitations
The main limitation of this review in terms of permitting
comparative statements and analyses is the level of het-
erogeneity in both sampling/survey methodology as well
as outcome variables (compliance calculations) among
the selected studies. Unlike the Babu & Babu review, we
did not recalculate the outcome variables to make them
comparable across studies, as one of the main objectives
of this paper was precisely that—to investigate and
highlight the lack of (and need for) such uniformity. The
authors purposefully did not apply very strict quality ap-
praisal to the study designs in order to include data from
as many endemic areas as possible. This review has
taken a fairly collective perspective on PCT compliance
in the NTD treatment programmes while focusing less
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Fig. 8 Individual-based stochastic model of STH transmission dynamics and MDA treatment. Elimination curves are shown for different patterns in
individual compliance to PCT treatment, targeted at pre-SAC and SAC at 75 % coverage. The blue line represents a random compliance setting where
individual participation is randomly allocated at each treatment. The green line represents a fully systematic compliance setting where an individual
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on disease- or programme-specific discussions, as is often
the case in the “siloed” research and policy communities.
While there are lessons to be learned from the successes
and failures of different programmes, there are a set of
universal issues and needs to be addressed in all disease
areas—especially given the increasing trend for integrating
control programmes that target multiple infections.
Conclusion
Reframing of the guidelines on compliance definitions
coupled with an urgent call for longitudinal research
in systematic non-compliance should be essential
elements in the programmatic shift from control to
elimination. With such ambitious goals set out before
us, we must first and foremost consider our approach
to the data and how we report it, if we are to draw
any meaningful conclusions from our research and
our programmes. The process of standardisation will
be both a source of awareness of the shortcomings in
compliance data and research, but it will also be,
undoubtedly, the source of greater clarity, progress
and successful steps toward elimination. We believe
there would be much merit in modifying the current
approach for reporting compliance; for example,
including fields (with corresponding definitions) for
both ‘coverage’ and ‘compliance’ in WHO’s Joint
Reporting Form for PCT thereby distinguishing the
two metrics and potentially clarifying any discrepancy
in language. Having a common digital template to
guide the collection of data and its storage on an
open access web site is essential. The imprimatur of
WHO and major funders of NTD work should
continue to facilitate this and to encourage countries
to contribute their data. The benefit to the countries
is a better understanding of the potential impact on
the burden of infection and disease of the PCT
programmes they are implementing.
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